Methods of inhibiting cancer cell growth with HDAC inhibitors and methods of screening for HDAC10 inhibitors
Methods of inhibiting cancer cell growth using HDAC10 inhibitors are provided. Methods of treating cancer in a subject using HDAC10 inhibitors are also provided. In certain embodiments, at least one second inhibitor selected from an autophagy inhibitor, an AMPK inhibitor, and methyl pyruvate is also used in the methods. Dose packs comprising HDAC10 inhibitors and at least one second inhibitor are provided. Methods of identifying HDAC10 inhibitors are also provided.
1. A method of inhibiting cancer cell growth comprising contacting the cancer cell with at least one HDAC10 inhibitor and at least one second inhibitor selected from an autophagy inhibitor and an AMPK inhibitor, wherein the cancer is selected from lung, cervical, prostate, and ovarian cancer.
2. The method of claim 1 , wherein at least one HDAC10 inhibitor is a pan HDAC inhibitor.
3. The method of claim 2 , wherein the pan HDAC10 inhibitor is selected from hydroxamic acid based HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and its derivatives, NVP-LAQ824, LBH589, trichostatin A, scriptaid, m-carboxycinnamic acid bishydroxamic acid (CBHA), ABHA, pyroxamide, propenamides, oxamflatin, 6-(3-Chlorophenylureido)caproic hydroxamic acid (3-CI-UCHA), A-161906, jnj16241199, tubacin and tubacin analogs, short chain fatty acid HDAC inhibitors, butyrate, phenylbutyrate, hydroxamic acid, trichostatins, epoxyketone-containing cyclic tetrapeptides, HC-toxin, chlamydocin, diheteropeptide, WF-3161, Cyl-1, Cyl-2, non-epoxyketone-containing cyclic tetrapeptides, apicidin, cyclic-hydroxamic-acid-containing peptides (CHAPS), benzamides and benzamide analogs, CI-994, trapoxin, deprudecin, and organosulfur compounds.
4. The method of claim 1 , wherein the autophagy inhibitor is selected from chloroquine or 3-methyladenine.
5. The method of claim 1 , wherein the AMPK inhibitor is Compound C.
6. The method of claim 1 , wherein the cell is contacted in a subject.
7. The method of claim 6 , wherein the subject is human.
8. A method of treating cancer comprising administering to a subject at least one HDAC10 inhibitor and at least one second inhibitor selected from an autophagy inhibitor and an AMPK inhibitor, wherein the cancer is selected from lung, cervical, prostate, and ovarian cancer.
9. The method of claim 8 , wherein at least one HDAC10 inhibitor is a pan HDAC inhibitor.
10. The method of claim 9 , wherein the pan HDAC10 inhibitor is selected from hydroxamic acid based HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and its derivatives, NVP-LAQ824, LBH589, trichostatin A, scriptaid, m-carboxycinnamic acid bishydroxamic acid (CBHA), ABHA, pyroxamide, propenamides, oxamflatin, 6-(3-Chlorophenylureido)caproic hydroxamic acid (3-CI-UCHA), A-161906, jnj16241199, tubacin and tubacin analogs, short chain fatty acid HDAC inhibitors, butyrate, phenylbutyrate, hydroxamic acid, trichostatins, epoxyketone-containing cyclic tetrapeptides, HC-toxin, chlamydocin, diheteropeptide, WF-3161, Cyl-1, Cyl-2, non-epoxyketone-containing cyclic tetrapeptides, apicidin, cyclic-hydroxamic-acid-containing peptides (CHAPS), benzamides and benzamide analogs, CI-994, trapoxin, deprudecin, and organosulfur compounds.
11. The method of claim 8 , wherein the autophagy inhibitor is selected from chloroquine or 3-methyladenine.
12. The method of claim 8 , wherein the AMPK inhibitor is Compound C.
13. A method of inhibiting cancer cell growth comprising contacting the cancer cell with at least one HDAC10 inhibitor and methylpyruvate, wherein the cancer is lung cancer.
14. The method of claim 13 , wherein at least one HDAC10 inhibitor is a pan HDAC inhibitor.
15. The method of claim 14 , wherein the pan HDAC10 inhibitor is selected from hydroxamic acid based HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and its derivatives, NVP-LAQ824, LBH589, trichostatin A, scriptaid, m-carboxycinnamic acid bishydroxamic acid (CBHA), ABHA, pyroxamide, propenamides, oxamflatin, 6-(3-Chlorophenylureido)caproic hydroxamic acid (3-CI-UCHA), A-161906, jnj16241199, tubacin and tubacin analogs, short chain fatty acid HDAC inhibitors, butyrate, phenylbutyrate, hydroxamic acid, trichostatins, epoxyketone-containing cyclic tetrapeptides, HC-toxin, chlamydocin, diheteropeptide, WF-3161, Cyl-1, Cyl-2, non-epoxyketone-containing cyclic tetrapeptides, apicidin, cyclic-hydroxamic-acid-containing peptides (CHAPS), benzamides and benzamide analogs, CI-994, trapoxin, deprudecin, and organosulfur compounds.
16. The method of claim 13 , wherein the cell is contacted in a subject.
17. The method of claim 16 , wherein the subject is human.
18. A method of treating cancer comprising administering to a subject at least one HDAC10 inhibitor and methylpyruvate, wherein the cancer is lung cancer.
19. The method of claim 18 , wherein at least one HDAC10 inhibitor is a pan HDAC inhibitor.
20. The method of claim 19 , wherein the pan HDAC10 inhibitor is selected from hydroxamic acid based HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and its derivatives, NVP-LAQ824, LBH589, trichostatin A, scriptaid, m-carboxycinnamic acid bishydroxamic acid (CBHA), ABHA, pyroxamide, propenamides, oxamflatin, 6-(3-Chlorophenylureido)caproic hydroxamic acid (3-CI-UCHA), A-161906, jnj16241199, tubacin and tubacin analogs, short chain fatty acid HDAC inhibitors, butyrate, phenylbutyrate, hydroxamic acid, trichostatins, epoxyketone-containing cyclic tetrapeptides, HC-toxin, chlamydocin, diheteropeptide, WF-3161, Cyl-1, Cyl-2, non-epoxyketone-containing cyclic tetrapeptides, apicidin, cyclic-hydroxamic-acid-containing peptides (CHAPS), benzamides and benzamide analogs, CI-994, trapoxin, deprudecin, and organosulfur compounds.